PD-L1 expression in nonclear-cell renal cell carcinoma
PD-L1 expression in nonclear-cell renal cell carcinoma
复制标题
DOI：
10.1093/annonc/mdu445
复制
发表时间：
2014-11-01
影响因子：
50.5
通讯作者：
Signoretti, S.
中科院分区：
文献类型：
--
作者：
Choueiri, T. K.;Fay, A. P.;Signoretti, S.
程序性死亡配体-1（PD-L1）在非透明细胞肾细胞癌（non-ccRCC）中的表达及其与临床结局的关系尚不清楚。在这项研究中，我们报告了PD-L1表达发生在非ccRCC患者中，这取决于组织学亚型和肿瘤细胞膜与免疫细胞评分。此外，我们发现PD-L1阳性肿瘤患者在非ccRCC中的临床结局似乎更差。非透明细胞RCC（non-ccRCC）中的程序性死亡配体-1（PD-L1）表达及其与临床结局的关系尚不清楚。福尔马林固定石蜡包埋（FFPE）标本来自101例非ccRCC患者。通过免疫组织化学评价肿瘤细胞膜和肿瘤浸润单核细胞（TIMC）中的PD-L1表达。PD-L1肿瘤阳性定义为每千日元5%肿瘤细胞膜染色的份数。对于TIMC中的PD-L1表达，使用基于浸润程度和阳性细胞百分比的组合评分。基线临床病理特征和结果数据[复发时间（TTR）和总生存期（OS）]与PD-L1染色相关。（10.9%）被认为是肿瘤细胞中的PD-L1+：嫌色细胞癌2/36（5.6%），乳头状细胞癌5/50（10%），Xp11.2易位细胞癌3/10（30%），集合管癌1/5（20%）。肿瘤细胞PD-L1阳性（PD-L1+）与肿瘤分期（P = 0.01）、分级（P = 0.03）及生存期（P < 0.001）相关。另一方面，在57例（56.4%）患者中观察到PD-L1阳性：嫌色细胞RCC 13/36（36.1%），乳头状RCC 30/50（60%），Xp11.2易位RCC 9/10（90%）和集合管癌5/5（100%）。在TIMC中PD-L1+患者中观察到OS缩短的趋势（P = 0.08）。肿瘤细胞膜和TIMC细胞中的PD-L1+与较短的TTR相关（分别为P = 0.02和P = 0.03）。在非ccRCC中，PD-L1+肿瘤患者的临床结局似乎较差，尽管仅肿瘤细胞中的PD-L1阳性与较高的肿瘤分期和分级相关。
Programmed death ligand-1 (PD-L1) expression in nonclear-cell RCC (non-ccRCC) and its association with clinical outcomes are unknown. In this study, we report that PD-L1 expression occurs in patients with non-ccRCC depending on histology subtype and tumour cell membrane versus immune cell scoring. In addition, we showed that patients with PD-L1-positive tumours appear to have worse clinical outcomes in non-ccRCC .Programmed death ligand-1 (PD-L1) expression in nonclear-cell RCC (non-ccRCC) and its association with clinical outcomes are unknown.Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 101 patients with non-ccRCC. PD-L1 expression was evaluated by immunohistochemistry in both tumor cell membrane and tumor-infiltrating mononuclear cells (TIMC). PD-L1 tumor positivity was defined as a parts per thousand yen5% tumor cell membrane staining. For PD-L1 expression in TIMC, a combined score based on the extent of infiltrate and percentage of positive cells was used. Baseline clinico-pathological characteristics and outcome data [time to recurrence (TTR) and overall survival (OS)] were correlated with PD-L1 staining.Among 101 patients, 11 (10.9%) were considered PD-L1+ in tumor cells: 2/36 (5.6%) of chromophobe RCC, 5/50 (10%) of papillary RCC, 3/10 (30%) of Xp11.2 translocation RCC and 1/5 (20%) of collecting duct carcinoma. PD-L1 positivity (PD-L1+) in tumor cells was significantly associated with higher stage (P = 0.01) and grade (P = 0.03), as well as shorter OS (P < 0.001). On the other hand, PD-L1 positivity by TIMC was observed in 57 (56.4%) patients: 13/36 (36.1%) of chromophobe RCC, 30/50 (60%) of papillary RCC, 9/10 (90%) of Xp11.2 translocation RCC and 5/5 (100%) of collecting duct carcinoma. A trend toward shorter OS was observed in patients with PD-L1+ in TIMC (P = 0.08). PD-L1+ in both tumor cell membrane and TIMC cells were associated with shorter TTR (P = 0.02 and P = 0.03, respectively).In non-ccRCC, patients with PD-L1+ tumors appear to have worse clinical outcomes, although only PD-L1 positivity in tumor cells is associated with higher tumor stage and grade.